Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

FLT3 mutations are the most common genetic aberrations found in acute myeloid leukemia
(AML) and associated with poor prognosis. Since the discovery of FLT3 mutations and their …

The FLT3 receptor is overexpressed on the majority of acute myeloid leukemia (AML) blasts.
Mutations in FLT3 are the most common genetic alteration in AML, identified in …

Pexidartinib (TURALIO™) is an orally administered small molecule tyrosine kinase inhibitor
with selective activity against the colony-stimulating factor 1 (CSF1) receptor, KIT proto …

Advances in the understanding of the molecular basis for acute myeloid leukemia (AML)
have generated new potential targets for treatment. Fms-like tyrosine kinase 3 (FLT3) is one …

Clinically acquired resistance is a major challenge in cancer therapies with small-molecule
kinase inhibitors (SMKIs). Gatekeeper mutations in the ATP-binding pocket of kinases are …

Compared with traditional therapies, targeted therapy has merits in selectivity, efficacy, and
tolerability. Small molecule inhibitors are one of the primary targeted therapies for cancer …

FLT3 mutations are prevalent in AML patients and confer poor prognosis. Crenolanib, a
potent type I pan-FLT3 inhibitor, is effective against both internal tandem duplications and …

Activating mutations in FLT3 occur in~ 30% of adult acute myeloid leukemia, primarily
consisting of internal tandem duplication (ITD) mutations (~ 25%) and point mutations in the …